NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products

This is sponsored content.  Barchart is not endorsing the websites or products set forth below.

NEXGEL Inc. (NXGL), a company that makes medical gels for healthcare and beauty, announced on March 10, 2026 a definitive agreement to license and acquire a new line of advanced medical products from Celularity Inc. (CELU). 

This transaction, subject to customary closing conditions and financing, is a game-changer because it is expected to triple NEXGEL's annual revenue to $35 million and make the company profitable as soon as the deal closes. This shifts NEXGEL from being a gel manufacturer to a major player in medical technology.

The announcement follows NEXGEL's February disclosure of $1.797 million in initial financing tied to the potential acquisition, with the company now expecting to close on approximately $14.9 million in additional financing in Q1 2026 or early Q2 2026. 

"This is a transformative moment for our company," said Adam Levy, CEO. "We are acquiring a profitable, revenue-generating regenerative biomaterials platform — along with the talented team behind it — that will approximately triple our revenue, expects to make us immediately profitable, and fundamentally reposition NEXGEL as a growing force in medical technology."

Strategic Acquisitions Drive a Clear Path to Immediate Profitability

The Celularity portfolio encompasses six commercial-stage regenerative biomaterial products targeting tendon repair, skin grafts, and bone growth. These are not developmental assets. The portfolio carries over a decade of clinical use, demonstrated utility, and existing insurance reimbursement pathways, with favorable reimbursement changes taking effect in 2026.

An experienced commercial and scientific team is expected to join NEXGEL as part of the transaction, meaningfully expanding the company's sales reach from day one. Three additional 510(k) filings are planned for 2026, 2027, and 2028, extending the pipeline well beyond the current six products.

This follows the same disciplined playbook NEXGEL used to acquire Silly George and Kenkoderm, buying revenue-generating assets at value and integrating them into an established operational infrastructure.

"Building on the success of our Silly George and Kenkoderm acquisitions, NEXGEL is applying the same disciplined, value-driven approach," Levy said. "With established products, strong reimbursement dynamics, a deep pipeline, and an experienced sales organization that greatly expands our reach, we believe this transaction positions NEXGEL to drive sustainable growth, margin expansion, and long-term shareholder value. These pieces fit together nicely."

Proprietary Hydrogel Platform Anchors a Durable Competitive Position

The most durable businesses in any industry are those built on economic moats, which are proprietary advantages that are difficult for competitors to cross. 

NEXGEL is building several. Its 16,500 square foot cGMP manufacturing facility, producing electron-beam, cross-linked hydrogels for over two decades, is exactly that kind of infrastructure. FDA-registered, ISO-certified, and developed over two decades, it supports every product the company makes or acquires.

The company's four proprietary gel formulations span wound care, transdermal drug delivery, beauty, and biodegradable applications. That platform flexibility is what makes the Celularity acquisition a natural extension rather than a departure. 

NEXGEL is adding clinically validated, reimbursed products on top of the manufacturing and R&D capabilities it already owns. The combined entity brings complementary biomaterials and hydrogel technologies across multiple verticals, opening new distribution channels for both the acquired products and NEXGEL's existing portfolio.

A Platform Built for Three of the Largest Markets in Healthcare and Consumer Goods

The Celularity acquisition positions NEXGEL at the intersection of three expanding markets:

• OTC drugs: $142.27 billion in 2025, projected to reach $268.32 billion by 2035 at a 6.55% CAGR (Towards Healthcare)
• U.S. beauty and personal care: $109.56 billion in 2025, projected to reach $196.33 billion by 2033 at a 7.7% CAGR (Grand View Research)
• U.S. healthcare: $4.87 trillion in 2025, projected to reach $8.09 trillion by 2034 at a 5.8% CAGR (Market Data Forecast)

NEXGEL does not need to capture a large share of any one market to create meaningful shareholder value. The diversified revenue base across consumer, clinical, and professional channels provides multiple paths to growth.

The Bull Case for NXGL

For investors evaluating exposure to a profitable, platform-driven life sciences company with a clear acquisition strategy and expanding commercial footprint, the case for NXGL rests on fundamentals that are already in place rather than projections that have yet to materialize.

• Immediate profitability expected upon closing. The acquired products are already commercial, already reimbursed, and already revenue-generating. This is not a turnaround. It is an accretive addition to an existing business.
• Revenue expected to approximately triple. A jump to roughly $35 million in annual revenue, if realized, represents a fundamental change in the company's scale and market positioning.
• Reimbursement tailwinds arrive in 2026. Favorable reimbursement changes taking effect this year should support revenue growth across the acquired portfolio from the start.
• 510(k) pipeline extends the runway. Three planned filings through 2028 provide visible catalysts beyond the current portfolio.
• Proven acquisition playbook reduces execution risk. NEXGEL has successfully closed and integrated prior acquisitions. The Celularity transaction follows the same framework at a larger scale.
• Proprietary manufacturing creates durable advantages. Two decades of hydrogel IP, cGMP infrastructure, and platform flexibility are not easily replicated by competitors.

The combination of disciplined capital allocation, a repeatable acquisition model, and industry-leading products across beauty, OTC, and clinical biomaterials positions NEXGEL to become a meaningful force in life sciences, one where blended business lines and experienced leadership compound value over time rather than chase it.

The above is sponsored content. Barchart was paid up to fourteen thousand eight hundred fifty dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of March 2026.  For more information please view the Barchart Disclosure Policy here.